Valuation: Collegium Pharmaceutical, Inc.

Market Cap 72Cr 64Cr 60Cr 54Cr 102.11Cr 6.9TCr 102.86Cr 719.93Cr 280.1Cr 3.52TCr 269.11Cr 263.31Cr 11TCr P/E 2026 *
13.2x
P/E 2027 * 6.61x
Enterprise Value 156.82Cr 139.9Cr 130.34Cr 118.61Cr 223.37Cr 15TCr 225.03Cr 1.57TCr 612.75Cr 7.71TCr 588.72Cr 576.02Cr 25TCr EV / Sales 2026 *
1.87x
EV / Sales 2027 * 1.49x
Free-Float
77.39%
Yield 2026 *
-
Yield 2027 * -
1 week-1.01%
Current month+1.03%
1 month-5.77%
3 months-39.51%
6 months-30.05%
Current year-53.33%
1 week 19.2
Extreme 19.2
20.2
1 month 18.9
Extreme 18.9
20.8
3 years 18.9
Extreme 18.9
42.4
Manager TitleAgeSince
Chief Executive Officer 51 12/11/2024
Director of Finance/CFO 50 24/05/2021
Chief Tech/Sci/R&D Officer 65 23/03/2022
Director TitleAgeSince
Chairman 69 15/05/2025
Director/Board Member 72 01/02/2014
Director/Board Member 78 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%-1.01%-33.33%-9.26% 72Cr
+0.02%-3.41%+36.11%+115.09% 1,01900Cr
-1.21%-6.74%+34.08%+62.64% 62TCr
+1.12%+0.54%+13.62%+79.94% 46TCr
-3.30%-6.21%+56.45%+36.58% 36TCr
+0.93%-3.16%+21.65%+43.02% 33TCr
+0.12%-2.77%+10.70%+32.97% 27TCr
-0.89%-6.28%-7.00%+8.01% 24TCr
-0.01%-2.81%+35.28%+51.82% 22TCr
-0.08%-4.17%+28.34%+93.51% 18TCr
Average -0.77%-3.54%+19.59%+51.43% 41.08TCr
Weighted average by Cap. -0.54%-3.54%+28.49%+70.09%

Financials

2026 *2027 *
Net sales 84Cr 75Cr 70Cr 63Cr 119.24Cr 8.06TCr 120.12Cr 840.7Cr 327.08Cr 4.11TCr 314.26Cr 307.48Cr 13TCr 85Cr 76Cr 71Cr 64Cr 121.09Cr 8.19TCr 121.98Cr 853.74Cr 332.16Cr 4.18TCr 319.13Cr 312.25Cr 13TCr
Net income 6.1Cr 5.44Cr 5.07Cr 4.61Cr 8.69Cr 587.55Cr 8.75Cr 61Cr 24Cr 299.88Cr 23Cr 22Cr 963.91Cr 13Cr 12Cr 11Cr 9.84Cr 19Cr 1.25TCr 19Cr 130.68Cr 51Cr 639.64Cr 49Cr 48Cr 2.06TCr
Net Debt 85Cr 76Cr 71Cr 64Cr 121.27Cr 8.2TCr 122.16Cr 855Cr 332.65Cr 4.18TCr 319.61Cr 312.71Cr 13TCr 55Cr 49Cr 46Cr 42Cr 79Cr 5.33TCr 79Cr 555.44Cr 216.1Cr 2.72TCr 207.63Cr 203.15Cr 8.74TCr
Logo Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.
Employees
-
Date Price Change
06/26/06 €19.50 -0.51%
02/26/02 €19.60 +0.51%
01/26/01 €19.50 +0.52%
30/26/30 €19.40 0.00%
29/26/29 €19.40 -2.51%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
22.02USD
Average target price
49.00USD
Spread / Average Target
+122.52%

Quarterly revenue - Rate of surprise